新冠后持续抑郁和认知症状者的星形胶质细胞增生标志物[11C]SL25.1188
本研究用正电子发射断层扫描测量21例新冠后持续抑郁和认知症状(COVID-DC)患者与21名健康对照的[11C]SL25.1188总分布容积(VT),该指标反映单胺氧化酶B密度和星形胶质细胞增生。COVID-DC患者前额叶皮层、前扣带回皮层、海马、背侧壳核和腹侧纹状体VT均高于健康对照,抑郁症状严重程度与VT呈负相关,急性感染距今更近与VT正相关。探索性分析显示COVID-DC患者海马、背侧壳核和腹侧纹状体VT高于无新冠感染史的重性抑郁发作对照,优先脑区VT与认知测试无关联。
要点
- COVID-DC患者前额叶皮层、前扣带回皮层、海马、背侧壳核和腹侧纹状体[11C]SL25.1188 VT高于健康对照。
- 抑郁症状严重程度与优先脑区[11C]SL25.1188 VT呈负相关。
- 急性感染距今更近与[11C]SL25.1188 VT正相关,奥密克戎变异株流行后VT更高。
核心结论
- 结果强烈支持COVID-DC患者所评估脑区存在单胺氧化酶B标记的星形胶质细胞增生,但星形胶质细胞增生越明显症状越少,提示可能具有保护作用。
- 奥密克戎变异株出现后,COVID-DC中星形胶质细胞增生程度更高。
研究设计与样本
- 研究纳入21例COVID-DC患者和21名健康对照,用正电子发射断层扫描测量[11C]SL25.1188 VT。
- 测量脑区包括前额叶皮层、前扣带回皮层、海马、背侧壳核和腹侧纹状体。
- 抑郁症状用贝克抑郁量表第二版评估,认知症状用神经心理测试评估。
主要发现
- COVID-DC患者前额叶皮层、前扣带回皮层、海马、背侧壳核和腹侧纹状体[11C]SL25.1188 VT高于健康对照。
- 抑郁症状严重程度与优先脑区[11C]SL25.1188 VT呈负相关。
- 急性感染距今更近与[11C]SL25.1188 VT正相关,反映奥密克戎变异株流行后数值更高。
- 探索性分析显示COVID-DC患者海马、背侧壳核和腹侧纹状体VT高于无新冠感染史的重性抑郁发作对照。
- 优先脑区[11C]SL25.1188 VT与认知测试无关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After acute COVID-19, 5% of people experience persistent depressive symptoms and reduced cognitive function (COVID-DC). Theoretical models propose that astrogliosis is important in long COVID, but measures primarily indicative of astrogliosis have not been studied in the brain of long COVID or COVID-DC. The objective of the current study was to measure [11C]SL25.1188 total distribution volume ([11C]SL25.1188 VT), an index of monoamine oxidase B density and a marker of astrogliosis, with positron emission tomography in participants with COVID-DC and compare with healthy control participants. METHODS: In 21 COVID-DC cases and 21 healthy control participants, [11C]SL25.1188 VT was measured in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum. Depressive symptoms were measured with the Beck Depression Inventory-II, and cognitive symptoms were measured with neuropsychological tests. RESULTS: [11C]SL25.1188 VT was higher in participants with COVID-DC in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum than in healthy control participants. Depressive symptom severity negatively correlated with [11C]SL25.1188 VT across prioritized brain regions. More recent acute COVID-19 positively correlated with [11C]SL25.1188 VT, reflecting higher values since predominance of the Omicron variant. Exploratory analyses found greater [11C]SL25.1188 VT in the hippocampus, dorsal putamen, and ventral striatum of COVID-DC participants than control participants with a major depressive episode with no history of COVID-19, and there was no relationship to cognitive testing in prioritized regions. CONCLUSIONS: Results strongly support the presence of monoamine oxidase B-labeled astrogliosis in COVID-DC throughout the regions assessed, although the association of greater astrogliosis with fewer symptoms raises the possibility of a protective role. The magnitude of astrogliosis in COVID-DC is greater since the emergence of the Omicron variant.
引用
- Braga J, Kuik EJY, Lepra M, et al. Astrogliosis Marker [11C]SL25.1188 After COVID-19 With Ongoing Depressive and Cognitive Symptoms. Biol Psychiatry. 2024. PMID: 39395470. doi:10.1016/j.biopsych.2024.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。